Testing the drug HMPL-306 for grade 2 glioma with an IDH gene change
Original title: HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a large late stage trial, but the drug is still being tested.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests a drug called HMPL-306 in people whose grade 2 glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary has an IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary or IDH2 gene change.
Who this trial is for. This trial is for people with a grade 2 glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary that has an IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary or IDH2 gene change, and whose tumor is left over after surgery or has come back. Some people get HMPL-306 and some get a placebo, which looks the same but has no drug in it, and no one knows who got which.
Where it stands. The trial is measuring how well HMPL-306 works and how safe it is. Those answers are not in yet. The trial has not reported results.
What this means, and what it doesn't
What it could mean: We do not yet know if this drug helps. Someone whose tumor fits this picture could ask their care team about it.
What it doesn't mean: This does not mean HMPL-306 works. A trial is a test, not a proven treatment. Being in a trial is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, November 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.